National Kidney Foundation: FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
September 30, 2019
September 30, 2019
NEW YORK, Sept. 30 -- The National Kidney Foundation issued the following news release:
"The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that their drug INVOKANA(R) (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (CKD). It is the first new treatment for diabetic kidney disease ( . . .
"The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that their drug INVOKANA(R) (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (CKD). It is the first new treatment for diabetic kidney disease ( . . .